| References: |
RVX-208 is a selective antagonist of BET bromodomains, binding with 10-100-fold higher affinity for BD2 (IC50 = 0.04-0.28 µM) over BD1 (IC50 = 1.8-3.1 µM).RVX-208 causes the selective release of BET proteins from chromatin in cells.It interferes with the BET protein BRD4, resulting in an increased expression of apolipoprotein (Apo) A1 in cells, mice, monkeys, and humans.RVX-208 also reduces atherosclerosis in hyperlipidemic ApoE-deficient mice. For the detailed information of RVX-208, the solubility of RVX-208 in water, the solubility of RVX-208 in DMSO, the solubility of RVX-208 in PBS buffer, the animal experiment (test) of RVX-208, the cell expriment (test) of RVX-208, the in vivo, in vitro and clinical trial test of RVX-208, the EC50, IC50,and affinity,of RVX-208, For the detailed information of RVX-208, the solubility of RVX-208 in water, the solubility of RVX-208 in DMSO, the solubility of RVX-208 in PBS buffer, the animal experiment (test) of RVX-208, the cell expriment (test) of RVX-208, the in vivo, in vitro and clinical trial test of RVX-208, the EC50, IC50,and affinity,of RVX-208, Please contact DC Chemicals. |
